Clinical Trial Update: Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of elotuzumab combined with lenalidomide and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Elotuzumab (elotuzumab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2022-10-17